Integra Lifesciences Holdings (IART) EBIAT (2016 - 2025)
Historic EBIAT for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$5.4 million.
- Integra Lifesciences Holdings' EBIAT rose 4947.17% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$495.3 million, marking a year-over-year decrease of 746930.01%. This contributed to the annual value of -$6.9 million for FY2024, which is 11025.08% down from last year.
- According to the latest figures from Q3 2025, Integra Lifesciences Holdings' EBIAT is -$5.4 million, which was up 4947.17% from -$484.1 million recorded in Q2 2025.
- Integra Lifesciences Holdings' 5-year EBIAT high stood at $52.9 million for Q4 2022, and its period low was -$484.1 million during Q2 2025.
- Over the past 5 years, Integra Lifesciences Holdings' median EBIAT value was $19.8 million (recorded in 2023), while the average stood at -$5.5 million.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 960352.3% in 2021, then crashed by 380318.5% in 2025.
- Quarter analysis of 5 years shows Integra Lifesciences Holdings' EBIAT stood at $45.4 million in 2021, then grew by 16.66% to $52.9 million in 2022, then crashed by 62.54% to $19.8 million in 2023, then dropped by 2.01% to $19.4 million in 2024, then tumbled by 127.81% to -$5.4 million in 2025.
- Its EBIAT was -$5.4 million in Q3 2025, compared to -$484.1 million in Q2 2025 and -$25.3 million in Q1 2025.